Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a dismal survival rate of only 3 years and no curative pharmacological therapy. The recent approval of 2 anti-fibrotic drugs (nintedanib and pirfenidone) that slow disease progression has provided some hope for patients. However, effec...

Full description

Saved in:
Bibliographic Details
Main Authors: Bendstrup, Elisabeth (Author) , Wuyts, Wim (Author) , Alfaro, Tiago M. (Author) , Chaudhuri, Nazia (Author) , Cornelissen, Robin (Author) , Kreuter, Michael (Author) , Melgaard Nielsen, Kirsten (Author) , Münster, Anna-Marie B. (Author) , Myllärniemi, Marjukka (Author) , Ravaglia, Claudia (Author) , Vanuytsel, Tim (Author) , Wijsenbeek, Marlies (Author)
Format: Article (Journal)
Language:English
Published: February 2019
In: Respiration
Year: 2019, Volume: 97, Issue: 2, Pages: 173-184
ISSN:1423-0356
DOI:10.1159/000495046
Online Access:Verlag, Volltext: https://doi.org/10.1159/000495046
Verlag, Volltext: https://www.karger.com/Article/FullText/495046
Get full text
Author Notes:Elisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, Nazia Chaudhuri, Robin Cornelissen, Michael Kreuter, Kirsten Melgaard Nielsen, Anna-Marie B. Münster, Marjukka Myllärniemi, Claudia Ravaglia, Tim Vanuytsel, Marlies Wijsenbeek

MARC

LEADER 00000caa a2200000 c 4500
001 1667900366
003 DE-627
005 20251011160743.0
007 cr uuu---uuuuu
008 190625s2019 xx |||||o 00| ||eng c
024 7 |a 10.1159/000495046  |2 doi 
035 |a (DE-627)1667900366 
035 |a (DE-599)KXP1667900366 
035 |a (OCoLC)1341230092 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bendstrup, Elisabeth  |e VerfasserIn  |0 (DE-588)1189169967  |0 (DE-627)1667900641  |4 aut 
245 1 0 |a Nintedanib in idiopathic pulmonary fibrosis  |b practical management recommendations for potential adverse events  |c Elisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, Nazia Chaudhuri, Robin Cornelissen, Michael Kreuter, Kirsten Melgaard Nielsen, Anna-Marie B. Münster, Marjukka Myllärniemi, Claudia Ravaglia, Tim Vanuytsel, Marlies Wijsenbeek 
264 1 |c February 2019 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 25.06.2019 
520 |a Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a dismal survival rate of only 3 years and no curative pharmacological therapy. The recent approval of 2 anti-fibrotic drugs (nintedanib and pirfenidone) that slow disease progression has provided some hope for patients. However, effectively managing anti-fibrotic treatment can be a challenge due to tolerability issues, the presence of pulmonary and extra-pulmonary comorbidities, and the need for concomitant medications in many patients. In general, making clear evidence-based decisions can be difficult for physicians because patients with comorbidities are often excluded from clinical trials. Since currently anti-fibrotic drugs are the only effective therapeutics capable of slowing disease progression, it is imperative that all treatment options are thoroughly evaluated and exhausted in each individual, irrespective of complicating factors, to permit the best outcome for the patient. In this review, we present data from clinical trials, post hoc analyses, post-marketing surveillance, and real-world studies that are relevant to the management of nintedanib treatment. In addition, we also provide practical recommendations developed by a multidisciplinary panel of experts for the management of nintedanib treatment in patients with IPF associated complications and those experiencing gastrointestinal side effects. 
700 1 |a Wuyts, Wim  |e VerfasserIn  |4 aut 
700 1 |a Alfaro, Tiago M.  |e VerfasserIn  |0 (DE-588)1207175358  |0 (DE-627)1693421909  |4 aut 
700 1 |a Chaudhuri, Nazia  |e VerfasserIn  |4 aut 
700 1 |a Cornelissen, Robin  |e VerfasserIn  |4 aut 
700 1 |a Kreuter, Michael  |d 1972-  |e VerfasserIn  |0 (DE-588)122645995  |0 (DE-627)082066795  |0 (DE-576)293362742  |4 aut 
700 1 |a Melgaard Nielsen, Kirsten  |e VerfasserIn  |4 aut 
700 1 |a Münster, Anna-Marie B.  |e VerfasserIn  |4 aut 
700 1 |a Myllärniemi, Marjukka  |e VerfasserIn  |4 aut 
700 1 |a Ravaglia, Claudia  |e VerfasserIn  |4 aut 
700 1 |a Vanuytsel, Tim  |e VerfasserIn  |4 aut 
700 1 |a Wijsenbeek, Marlies  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Respiration  |d Basel : Karger, 1968  |g 97(2019), 2, Seite 173-184  |h Online-Ressource  |w (DE-627)26551035X  |w (DE-600)1464419-8  |w (DE-576)112815111  |x 1423-0356  |7 nnas  |a Nintedanib in idiopathic pulmonary fibrosis practical management recommendations for potential adverse events 
773 1 8 |g volume:97  |g year:2019  |g number:2  |g pages:173-184  |g extent:12  |a Nintedanib in idiopathic pulmonary fibrosis practical management recommendations for potential adverse events 
856 4 0 |u https://doi.org/10.1159/000495046  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.karger.com/Article/FullText/495046  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190625 
993 |a Article 
994 |a 2019 
998 |g 122645995  |a Kreuter, Michael  |m 122645995:Kreuter, Michael  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PK122645995  |e 950000PK122645995  |e 950900PK122645995  |e 50000PK122645995  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 6 
999 |a KXP-PPN1667900366  |e 3489630165 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"subtitle":"practical management recommendations for potential adverse events","title":"Nintedanib in idiopathic pulmonary fibrosis","title_sort":"Nintedanib in idiopathic pulmonary fibrosis"}],"person":[{"given":"Elisabeth","role":"aut","roleDisplay":"VerfasserIn","display":"Bendstrup, Elisabeth","family":"Bendstrup"},{"given":"Wim","roleDisplay":"VerfasserIn","role":"aut","display":"Wuyts, Wim","family":"Wuyts"},{"display":"Alfaro, Tiago M.","roleDisplay":"VerfasserIn","role":"aut","given":"Tiago M.","family":"Alfaro"},{"display":"Chaudhuri, Nazia","role":"aut","roleDisplay":"VerfasserIn","given":"Nazia","family":"Chaudhuri"},{"family":"Cornelissen","given":"Robin","role":"aut","roleDisplay":"VerfasserIn","display":"Cornelissen, Robin"},{"display":"Kreuter, Michael","roleDisplay":"VerfasserIn","role":"aut","given":"Michael","family":"Kreuter"},{"family":"Melgaard Nielsen","display":"Melgaard Nielsen, Kirsten","role":"aut","roleDisplay":"VerfasserIn","given":"Kirsten"},{"display":"Münster, Anna-Marie B.","given":"Anna-Marie B.","role":"aut","roleDisplay":"VerfasserIn","family":"Münster"},{"family":"Myllärniemi","display":"Myllärniemi, Marjukka","given":"Marjukka","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Ravaglia","display":"Ravaglia, Claudia","role":"aut","roleDisplay":"VerfasserIn","given":"Claudia"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Tim","display":"Vanuytsel, Tim","family":"Vanuytsel"},{"family":"Wijsenbeek","given":"Marlies","role":"aut","roleDisplay":"VerfasserIn","display":"Wijsenbeek, Marlies"}],"language":["eng"],"name":{"displayForm":["Elisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, Nazia Chaudhuri, Robin Cornelissen, Michael Kreuter, Kirsten Melgaard Nielsen, Anna-Marie B. Münster, Marjukka Myllärniemi, Claudia Ravaglia, Tim Vanuytsel, Marlies Wijsenbeek"]},"physDesc":[{"extent":"12 S."}],"id":{"doi":["10.1159/000495046"],"eki":["1667900366"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"February 2019"}],"relHost":[{"language":["eng"],"disp":"Nintedanib in idiopathic pulmonary fibrosis practical management recommendations for potential adverse eventsRespiration","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1968-","publisher":"Karger","dateIssuedKey":"1968","publisherPlace":"Basel"}],"title":[{"title_sort":"Respiration","title":"Respiration","subtitle":"international journal of thoracic medicine"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Vol. 25, no. 1 (1968)-"],"note":["Gesehen am 03.07.2024"],"recId":"26551035X","part":{"volume":"97","issue":"2","text":"97(2019), 2, Seite 173-184","pages":"173-184","extent":"12","year":"2019"},"id":{"eki":["26551035X"],"zdb":["1464419-8"],"issn":["1423-0356"]}}],"note":["Gesehen am 25.06.2019"],"recId":"1667900366","type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a BENDSTRUPENINTEDANIB2019